Literature DB >> 7720747

Specific decrease of anti-pseudomonal IgA after anti-pseudomonal therapy in cystic fibrosis.

K de Boeck1, E Eggermont, M Smet, P van Reempts, H P van Bever, W J Stevens.   

Abstract

UNLABELLED: In patients with cystic fibrosis (CF) and chronic colonisation with Pseudomonas aeruginosa, specific anti-pseudomonal IgG and IgA, as well as serum immunoreactive protein C, WBC and differential count, ESR, pulmonary function and chest radiograph score were determined before and after a 2 week intravenous course of anti-pseudomonal antibiotics in 32 cases of acute exacerbation of pulmonary infection. Specific anti-pseudomonal IgA but not specific anti-pseudomonal IgG decreased significantly after treatment. Log of anti-pseudomonal IgA but not log anti-pseudomonal IgG correlated well with disease severity as assessed by the Brasfield chest radiograph score (r 0.57), forced expiratory volume in 1 s (r 0.6) as well as C-reactive protein (r 0.62).
CONCLUSION: Specific anti-pseudomonal IgA may be a better parameter than specific IgG in the follow up of lung infection in patients with CF, probably because it more closely reflects ongoing endobronchial infection, the major pathology in CF lungs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720747     DOI: 10.1007/bf01991922

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  14 in total

1.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.

Authors:  L E GIBSON; R E COOKE
Journal:  Pediatrics       Date:  1959-03       Impact factor: 7.124

2.  Five- to seven-year course of pulmonary function in cystic fibrosis.

Authors:  M Corey; H Levison; D Crozier
Journal:  Am Rev Respir Dis       Date:  1976-12

3.  Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

4.  Serum C-reactive protein in assessment of pulmonary exacerbations and antimicrobial therapy in cystic fibrosis.

Authors:  S Glass; C Hayward; J R Govan
Journal:  J Pediatr       Date:  1988-07       Impact factor: 4.406

5.  Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71.

Authors:  M B Mearns; G H Hunt; R Rushworth
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

6.  Local humoral immunity and immune reactions in the lungs of patients with cystic fibrosis.

Authors:  P O Schiøtz
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1981

7.  Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay.

Authors:  S S Pedersen; F Espersen; N Høiby
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

8.  IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  S M Cordon; J S Elborn; R J Rayner; E J Hiller; D J Shale
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

9.  Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration.

Authors:  R S Baltimore; C D Christie; G J Smith
Journal:  Am Rev Respir Dis       Date:  1989-12

10.  Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function.

Authors:  G B Winnie; R G Cowan
Journal:  Pediatr Pulmonol       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.